Charles (Chuck) Osborne, Jr joins the company from oncology group Innocrin Pharmaceuticals and would start the role with immediately
() has appointed the former chief financial officer (CFO) of an oncology therapeutics firm as its new finance boss.
The medical imaging firm said Charles (Chuck) Osborne, Jr, who joins the company from Innocrin Pharmaceuticals Inc, would begin the role with immediate effect and will replace outgoing CFO Bill Patrick, who would take up the post of financial controller at Polarean Inc, the group’s subsidiary.
Prior to his role at Innocrin, Osborne was CFO of anti-infective therapy group Scynexis Inc ().
Richard Hullihen, Polarean’s chief executive, said Osborne’s “previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function”.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE